The estimated Net Worth of Diego Cadavid is at least 707 千$ dollars as of 11 February 2022. Diego Cadavid owns over 928 units of Fulcrum Therapeutics Inc stock worth over 62,897$ and over the last 5 years he sold FULC stock worth over 93,983$. In addition, he makes 550,364$ as Senior Vice President - Clinical Development at Fulcrum Therapeutics Inc.
Sign up
Diego Cadavid FULC stock SEC Form 4 insiders trading
Diego has made over 10 trades of the Fulcrum Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 928 units of FULC stock worth 8,213$ on 11 February 2022.
The largest trade he's ever made was selling 2,143 units of Fulcrum Therapeutics Inc stock on 2 March 2020 worth over 37,245$. On average, Diego trades about 791 units every 49 days since 2019. As of 11 February 2022 he still owns at least 7,107 units of Fulcrum Therapeutics Inc stock.
You can see the complete history of Diego Cadavid stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Diego Cadavid biography
Dr. Diego Cadavid serves as Senior Vice President - Clinical Development of the Company. Dr. Cadavid currently serves as an adjunct professor at the University of Massachusetts Medical School. Dr. Cadavid previously served as senior medical director in the M.S Clinical Development Group at Biogen Inc., or Biogen, a biotechnology company, from January 2014 to September 2016 and as a director of the Neurology Clinical Group at Biogen from April 2008 to December 2013. Before joining Biogen, Dr. Cadavid spent nine years at Rutgers-New Jersey Medical School where he was Associate Professor of Neurology and Neuroscience. While working at Biogen, Dr. Cadavid served as a consultant at the Center for Immunology and Inflammatory Diseases at the Massachusetts General Hospital in Boston. Dr. Cadavid received an M.D. from Pontificia Universidad Javeriana in Bogota, Colombia.
What is the salary of Diego Cadavid?
As the Senior Vice President - Clinical Development of Fulcrum Therapeutics Inc, the total compensation of Diego Cadavid at Fulcrum Therapeutics Inc is 550,364$. There are 5 executives at Fulcrum Therapeutics Inc getting paid more, with Robert Gould having the highest compensation of 3,889,350$.
How old is Diego Cadavid?
Diego Cadavid is 54, he's been the Senior Vice President - Clinical Development of Fulcrum Therapeutics Inc since 2018. There are 8 older and 5 younger executives at Fulcrum Therapeutics Inc. The oldest executive at Fulcrum Therapeutics Inc is Mark J. Levin, 71, who is the Exec. Chairman.
What's Diego Cadavid's mailing address?
Diego's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON, MA, 02134.
Insiders trading at Fulcrum Therapeutics Inc
Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over 1,450,584$ worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth 50,137,344$ . The most active insiders traders include Sanofi、Plc Gsk、Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of 868,035$. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth 490,500$.
What does Fulcrum Therapeutics Inc do?
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
What does Fulcrum Therapeutics Inc's logo look like?
Complete history of Diego Cadavid stock trades at Fulcrum Therapeutics Inc、X4 Pharmaceuticals
Fulcrum Therapeutics Inc executives and stock owners
Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Robert Gould,
President, Chief Executive Officer, Director -
Owen Wallace,
Chief Scientific Officer -
Bryan Stuart,
Chief Operating Officer -
Dr. Judith A. Dunn Ph.D.,
Pres of R&D and Interim Chief Medical Officer -
Bryan E. Stuart,
Pres, CEO & Director -
Diego Cadavid,
Senior Vice President - Clinical Development -
james Geraghty,
Independent Director -
Kate Haviland,
Independent Director -
Alan Ezekowitz,
Independent Director -
James Collins,
Independent Director -
Curtis G. Oltmans J.D.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Mark J. Levin,
Exec. Chairman -
Mark Levin,
Independent Chairman of the Board -
Christina Tartaglia,
IR Contact Officer -
Katina Dorton,
Independent Director -
Christi Waarich,
Director of Corp. Communications & Investor Relations -
Gregory Tourangeau,
Controller & Principal Accounting Officer -
Esther P. Rajavelu,
CFO & Treasurer -
Nicole T. Gallagher,
Director of Admin. -
Peter G. Thomson,
VP of Fin. & Accounting -
Dr. Danny Reinberg,
Founder -
Prof. Jeannie T. Lee M.D., Ph.D.,
Founder -
Dr. Rudolf Jaenisch M.D., Ph.D.,
Founder -
Dr. Michael R. Green,
Founder -
Dr. Bradley E. Bernstein M.D., Ph.D.,
Founder -
Sonja Banks,
-
Colin Hill,
-
Sanofi,
10% owner -
Rock Ventures Iii, L.P.Thir...,
-
Dimensions Capital, L.P. 6,
10% owner -
32 Fund 2, Lp Section 32 Gp...,
-
Capital, Llc Casdin Partner...,
-
Rock Ventures Iv, L.P.Third...,
-
Plc Gsk,
-
Curtis Gale Oltmans,
Chief Legal Officer -
Peter G. Thomson,
VP Finance & Accounting -
Christopher Morabito,
Chief Medical Officer -
Christopher Moxham,
Chief Scientific Officer -
Judith Dunn,
See Remarks -
Greg Tourangeau,
Principal Accounting Officer -
Esther Rajavelu,
Chief Financial Officer -
Rock Ventures Iii, L.P.Thir...,
-
Alex Sapir,
See Remarks -
Patrick Taylor Horn,
Chief Medical Officer -
Melvin H. Iii Hayes,
Chief Operating Officer -
Santiago Arroyo,
Chief Medical Officer -
Capital Management, L.P.Ra ...,
-
Alan A Musso,
Chief Financial Officer